PLASMA AND CELLULAR ADRIAMYCIN CONCENTRATIONS IN PATIENTS WITH MYELOMA TREATED WITH 96-HOUR CONTINUOUS INFUSION

被引：45
|
作者：
SPETH, PAJ [1 ]
LINSSEN, PCM [1 ]
HOLDRINET, RSG [1 ]
HAANEN, C [1 ]
机构：
[1] ST RADBOUD UNIV HOSP,DEPT HEMATOL,NIJMEGEN,NETHERLANDS
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1987年 / 41卷 / 06期
关键词：
D O I：
10.1038/clpt.1987.92
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：661 / 665
页数：5
相关论文
共 50 条
  • [21] A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy for unresectable head and neck cancer
    Machtay, M
    Aviles, V
    Kligerman, MM
    Treat, J
    Weinstein, GS
    Weber, RS
    Mirza, N
    Chalian, AA
    Rosenthal, DI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (02): : 311 - 315
  • [22] Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion
    Wadler, S
    Makower, D
    Clairmont, C
    Lambert, P
    Fehn, K
    Sznol, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1553 - 1563
  • [23] Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein
    van Asperen, J
    van Tellingen, O
    Schinkel, AH
    Beijnen, JH
    ANNALS OF ONCOLOGY, 1998, 9 : 149 - 149
  • [24] Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein
    van Asperen, J
    van Tellingen, O
    Schinkel, AH
    Beijnen, JH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 289 (01): : 329 - 333
  • [25] A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer
    Moulder, Stacy L.
    Holmes, Frankie A.
    Tolcher, Anthony W.
    Thall, Peter
    Broglio, Kristine
    Valero, Vicente
    Buzdar, Aman U.
    Arbuck, Susan G.
    Seidman, Andrew
    Hortobagyi, Gabriel N.
    CANCER, 2010, 116 (04) : 814 - 821
  • [26] INFLUENCE OF A CONTINUOUS CIMETIDINE INFUSION ON LIDOCAINE PLASMA-CONCENTRATIONS IN PATIENTS
    PATTERSON, JH
    FOSTER, J
    POWELL, JR
    CROSS, R
    WARGIN, W
    CLARK, JL
    JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (08): : 607 - 609
  • [27] Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
    J Dhainaut
    M Antonelli
    P Wright
    M Belger
    M Cobas-Meyer
    M Mignini
    J Janes
    Critical Care, 12 (Suppl 2):
  • [28] Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer
    Breathnach, OS
    Kasturi, V
    Kaye, F
    Herscher, L
    Georgiadis, MS
    Edison, M
    Schuler, BS
    Pizzella, P
    Steinberg, SM
    O'Neil, K
    Johnson, BE
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (03): : 269 - 273
  • [29] 96-HOUR CONTINUOUS INFUSION OF CIS-PLATINUM, 5-FLUOROURACIL AND BLEOMYCIN IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA, UNEXPECTED ANEMIA
    RECONDO, G
    BENHAMED, M
    CVITKOVIC, E
    MARANDAS, P
    ARMAND, JP
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (11): : 1529 - 1533
  • [30] Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study
    West, HL
    Crowley, JJ
    Vance, RB
    Franklin, WA
    Livingston, RB
    Dakhil, SR
    Giguere, JK
    Rivkin, SE
    Kraut, M
    Chansky, K
    Gandara, DR
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1076 - 1080
12345